Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Summary

Investigations prospectively collected the SCLC patients who received current standard first-line treatment, the response was not progression disease(PD). and then participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity. This regimen is compared to the effects a observation without treatment after the first-line therapy. The aim of the study is therefore to evaluate the efficacy and safety of Anlotinib as maintenance treatment after first-line chemotherapy in SCLC patients.

Timeline

Start

2019-01-01

Primary completion

2020-01-01

Completion

2022-01-01

Drugs

Indications